MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

135.15
-0.74
-0.54%
After Hours: 135.15 0 0.00% 16:53 05/18 EDT
OPEN
135.39
PREV CLOSE
135.89
HIGH
138.44
LOW
134.23
VOLUME
241.38K
TURNOVER
--
52 WEEK HIGH
178.41
52 WEEK LOW
119.29
MARKET CAP
15.89B
P/E (TTM)
-17.9040
1D
5D
1M
3M
1Y
5Y
12 West Capital Management LP Buys Roblox Corp, Asana Inc, Longview Acquisition Corp II, Sells ...
GuruFocus News · 6h ago
Alnylam Pharmaceuticals Stock Is Believed To Be Possible Value Trap
GuruFocus News · 1d ago
AtonRa Partners Buys Riot Blockchain Inc, Tencent Holdings, CrowdStrike Holdings Inc, Sells ...
GuruFocus News · 1d ago
Alnylam Announces New Advances in ATTR Amyloidosis Program
--a^' Introduces New ATTR Program Aimed at Achieving Annual Dosing Regimen with Highly Potent and Reversible Effects; Expected IND Filing at or Around Year-end 2022 -
BusinessWire · 05/11 11:00
Integral Health Asset Management, LLC Buys Centene Corp, Danaher Corp, Intellia Therapeutics ...
GuruFocus News · 05/10 14:38
Sector Gamma As Buys Pfizer Inc, Baxter International Inc, Centene Corp, Sells Abbott ...
GuruFocus News · 05/10 14:38
Huntington’s Disease Treatment Market Emerging Growth Comprehensive Market Study Innovative Business Growth Outlook Forecasting By 2027
May 10, 2021 (AmericaNewsHour) -- Research Nester released a report titled “Huntington’s Disease Treatment Market: Global Demand Analysis & Opportunity...
AmericaNewsHour · 05/10 05:00
Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted
Zacks.com · 05/07 14:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALNY. Analyze the recent business situations of Alnylam Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALNY stock price target is 174.72 with a high estimate of 235.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 534
Institutional Holdings: 116.08M
% Owned: 98.75%
Shares Outstanding: 117.55M
TypeInstitutionsShares
Increased
139
4.87M
New
52
1.36M
Decreased
114
3.58M
Sold Out
33
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Independent Director
Michael Bonney
President/Chief Operating Officer
Yvonne Greenstreet
Chief Executive Officer/Director
John Maraganore
Chief Financial Officer/Executive Vice President
Jeffrey Poulton
Corporate Executive
Akshay Vaishnaw
Executive Vice President/Secretary
Laurie Keating
Independent Director
Dennis Ausiello
Independent Director
Olivier Brandicourt
Independent Director
Marsha Fanucci
Independent Director
Margaret Hamburg
Other
Agnieszka Gallagher
Independent Director
Steven Paul
Other
Tolga Tanguler
Independent Director
David Pyott
Independent Director
Colleen Reitan
Independent Director
Amy Schulman
Independent Director
Phillip Sharp
No Data
About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.